KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $117.0 million.

  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) fell 7.67% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.0 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $127.2 million for FY2024, which is 3.69% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $117.0 million for Q3 2025, which was down 5.08% from $123.2 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Shares Outstanding (Weighted Average) peaked at $142.4 million during Q2 2021, and registered a low of $117.0 million during Q3 2025.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $127.5 million, with a median of $127.2 million in 2024.
  • As far as peak fluctuations go, Halozyme Therapeutics' Shares Outstanding (Weighted Average) grew by 4.84% in 2021, and later decreased by 7.67% in 2025.
  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $140.8 million in 2021, then dropped by 3.96% to $135.2 million in 2022, then dropped by 2.30% to $132.1 million in 2023, then fell by 3.69% to $127.2 million in 2024, then fell by 7.67% to $117.0 million in 2025.
  • Its last three reported values are $117.0 million in Q3 2025, $123.2 million for Q2 2025, and $123.2 million during Q1 2025.